EUCTR2005-000705-59-IT进行中（未招募）不适用
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Clinical Trial of Epratuzumab in Patients with Acute Severe SLE Flares Excluding the Renal or Neurologic Systems
IMMUNOMEDICS0 个研究点开始时间: 2005年9月30日最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
1 期
A study to investigate the safety and efficacy of AMX0035 in patients with Amyotrophic Lateral SclerosisAmyotrophic Lateral Sclerosis (ALS)MedDRA version: 21.1Level: PTClassification code: 10002026Term: Amyotrophic lateral sclerosis Class: 100000004852CTIS2023-508511-23-00Amylyx Pharmaceuticals Inc.664
进行中（未招募）
不适用
AModerate to Severe Chronic Kidney DiseaseMedDRA version: 14.0Level: LLTClassification code 10064848Term: Chronic kidney diseaseSystem Organ Class: 10038359 - Renal and urinary disordersEUCTR2005-004990-13-CZMitsubishi Tanabe Pharma Corporation980
已完成
3 期
A Study To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast CancerBreast CancerJPRN-jRCT2080224179CHUGAI PHARMACEUTICAL CO., LTD.453
进行中（未招募）
1 期
A clinical trial to test if the combination of ertugliflozin with Sitagliptin is safe when compared to placebo in patients with Type 2 Diabetes whose sugar levels are not well controlled by diet and excercise.Treatment of type 2 diabetes mellitus (T2DM) with Inadequate Glycemic Control on Diet and ExerciseMedDRA version: 18.1Level: LLTClassification code 10063624Term: Type II diabetes mellitus inadequate controlSystem Organ Class: 100000004861EUCTR2014-001049-25-GBMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.300
进行中（未招募）
1 期
A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Study Evaluating the Efficacy and Safety of ALTU-135 Treatment in Patients with Cystic Fibrosis-Related Exocrine Pancreatic InsufficiencyPatients with Cystic Fibrosis-Related Exocrine Pancreatic InsufficiencyMedDRA version: 9.1Level: LLTClassification code 10011766Term: Cystic fibrosis pancreaticEUCTR2007-000171-41-SKAltus Pharmaceuticals Inc176